Status:
COMPLETED
Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.
Lead Sponsor:
Pfizer
Conditions:
Anxiety Neuroses
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.
Eligibility Criteria
Inclusion
- Must have completed the double-blind portion of the preceding trial
- Completed any protocol specified withdrawal phase and follow-up visits.
Exclusion
- Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.
Key Trial Info
Start Date :
January 1 2001
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
511 Patients enrolled
Trial Details
Trial ID
NCT00150449
Start Date
January 1 2001
End Date
March 1 2006
Last Update
July 14 2006
Active Locations (138)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
A-1040 Wien, Austria
2
Pfizer Investigational Site
Vienna, Austria, A-1050
3
Pfizer Investigational Site
Wein, Austria, A-1020
4
Pfizer Investigational Site
Brussels, Belgium, 1020